Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000591

Drug Information
NameZileuton
SynonymsAKOS000280127; C063449; CPD000466377; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea; DB00744; Abbot 64077; Bio-0924; Zileuton [USAN:INN:BAN]; C11H12N2O2S; Zyflo; ABBOTT-64077; 111406-87-2; FT-0082368; Zileutonum; Urea, N-(1-benzo(b)thien-2-ylethyl)-N-hydroxy-, (+-)-; Ziluton; S1443_Selleck; ABT-077; AC-13198; A 64077; CHEBI:10112; 154003-29-9; SMR000466377; ZYFLO, Zileuton; MLS001424079; Zyflo CR; D00414; NCGC00159453-02; MolPort-003-850-877; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; Prestwick0_001090; HMS2093H06; Zyflo Filmtab; SAM001246738; UNII-V1L22WVE2S; Zileuton (USP/INN); MLS000759510; ZILEUTON; 133305-01-8; CTI-02; CHEMBL93; AC1L1TCB; HMS2051M20; Urea, N-(1-benzo(b)thien-2-ylethyl)-N-hydroxy-; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; Abbott brand of zileuton; LS-158908; A-64077; Abbott 64077; CID60490; Zileutonum [INN-Latin]; HMS2089J12; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; MolPort-000-883-253; Leutrol; Zyflo (TN)
Trade NameZYFLO
CompanyCornerstone Therapeutics Inc
IndicationAsthma
[ICD9: 493   ICD10: J45]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,
15H,1H3,(H2,12,14)
InChIKeyMWLSOWXNZPKENC-UHFFFAOYSA-N
Canonical SMILESCC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O    
Therapeutic ClassAnti-Inflammatory Agents
CAS NumberCAS 111406-87-2
FormulaC11H12N2O2S
PubChem Compound IDCID 60490.
PubChem Substance IDSID 196786.
ChEBI10112;
TargetArachidonate 5-lipoxygenaseInhibitor[2][3][4][5][6][7]
Ref 1Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46. To Reference
Ref 25-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Mar 23. [Epub ahead of print] To Reference
Ref 35-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009 Mar;19(3):244-7. To Reference
Ref 4Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells. J Neurosci Res. 2009 Mar;87(4):991-1001. To Reference
Ref 5Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008 Oct 15;14(20):6525-30. To Reference
Ref 6Leukotrienes in respiratory disease. Paediatr Respir Rev. 2001 Sep;2(3):238-44. To Reference
Ref 7Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543